Sinew Pharma Inc. (TPEX:6634)

Singular Genomics Systems Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-150.37	-170.92	-140.18	-91.58	-82.01
Depreciation & Amortization	30.21	28.95	22.78	22.59	21.74
Other Amortization	0.1	0.03	0.03	0.06	0.12
Stock-Based Compensation	20.16	18	16.71	12.1	2.08
Other Operating Activities	-0.99	-0.86	-0.45	-0.41	0.01
Change in Accounts Receivable	0.42	0.23	-	0.15	-0.15
Change in Accounts Payable	-3.72	8.68	-	-	-
Change in Unearned Revenue	-	-	-0.33	0.85	-
Change in Other Net Operating Assets	-1.89	-2.16	7.67	-1.06	-1.05
Operating Cash Flow	-106.08	-118.05	-93.76	-57.32	-59.26
Capital Expenditures	-0.18	-7.21	-5.23	-2.18	-1.8
Sale (Purchase) of Intangibles	-1.15	-0.24	-0.66	-3.69	-0.9
Investment in Securities	-9	35.8	-213	-640	-251.5
Other Investing Activities	-6.36	-2.15	-2.26	-2.7	-2.53
Investing Cash Flow	-16.69	26.2	-221.15	-648.56	-256.72
Long-Term Debt Repaid	-6.46	-6.1	-2.76	-2.29	-1.84
Net Debt Issued (Repaid)	-6.46	-6.1	-2.76	-2.29	-1.84
Issuance of Common Stock	3.82	18.08	13.17	1,213	111.93
Financing Cash Flow	-2.65	11.98	10.41	1,210	110.09
Net Cash Flow	-125.42	-79.87	-304.49	504.35	-205.9
Free Cash Flow	-106.26	-125.26	-98.99	-59.5	-61.06
Free Cash Flow Margin	-	-	-30178.66%	-955.19%	-13217.10%
Free Cash Flow Per Share	-1.49	-1.78	-1.43	-1.00	-1.23
Cash Interest Paid	0.41	0.78	0.28	0.15	0.27
Levered Free Cash Flow	-63.29	-71.93	-51.5	-34.31	-264.67
Unlevered Free Cash Flow	-63.03	-71.44	-51.33	-34.22	-264.5
Change in Working Capital	-5.19	6.75	7.35	-0.07	-1.19

Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.